Jeffrey Bacha, BSc, MBA co-founded DelMar Pharmaceuticals in 2010 and has served as Chief Executive Officer and Chairman of the Company's board of directors since inception. Mr. Bacha is a seasoned executive leader with nearly twenty years of life sciences experience in the areas of operations, strategy and finance. His background includes successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. From July 2006 to August 2009, Mr. Bacha was Executive Vice President Corporate Affairs and Chief Operating Officer at Clera, Inc. Mr. Bacha has served as a member of the Board of Directors of Sernova Corp. (TSXV: SVA), a Canadian cell therapy company focused on diabetes and other metabolic diseases.
From March 2005 to July 2006 Mr. Bacha was Consultant and held various positions at Clera Inc., Urigen Holdings Inc. and XBiotech, Inc. From 1999 through 2004, he served as President & CEO of Inimex Pharmaceuticals, a venture-capital funded drug discovery and development company and is a former Senior Manager and Director of KPMG Health Ventures.
As of 2017, Mr. Bacha serves as a member of the National Brain Tumor Society's Research Roundtable. He holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego.
Onco’Zine is raising awareness of the impact of cancer, cancer diagnosis and treatment an publishes a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.